From: The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Covariate | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
p-value | HR | 95% CI | p-value | HR | 95% CI | |
PFS | ||||||
T2D | 0.009 | 1.810 | 1.104–2.969 | 0.048 | 1.833 | 1.005–3.345 |
Peripheral vascular disease | 0.664 | 0.818 | 0.446–1.499 | 0.887 | 0.961 | 0.555–1.662 |
Dementia | 0.092 | 0.587 | 0.081–4.233 | 0.162 | 2.149 | 0.734–6.289 |
Renal disease | 0.823 | 0.529 | 0.129–2.165 | 0.510 | 0.666 | 0.199–2.231 |
Obesity | 0.060 | 1.913 | 1.121–3.263 | 0.451 | 1.230 | 0.717–2.109 |
Hypercholesterolemia | 0.842 | 0.479 | 0.150–1.527 | 0.829 | 0.913 | 0.402–2.073 |
Hypertension | 0.064 | 1.204 | 0.615–2.361 | 0.941 | 1.029 | 0.480–2.205 |
Thyroiditis | 0.306 | 1.543 | 0.666–3.576 | 0.867 | 0.927 | 0.384–2.238 |
Chronic pulmonary disease | 0.289 | 0.282 | 0.069–1.154 | 0.126 | 0.498 | 0.204–1.216 |
Other comorbidities | 0.7791 | 1.112 | 0.654–1.890 | 0.507 | 1.180 | 0.722–1.929 |
OS | ||||||
T2D | 0.018 | 1.740 | 1.142–2.651 | 0.009 | 2.377 | 1.240–4.557 |
Peripheral vascular disease | 0.517 | 0.894 | 0.541–1.479 | 0.347 | 0.728 | 0.376–1.410 |
Dementia | 0.597 | 2.389 | 0.866–6.590 | 0.386 | 0.408 | 0.053–3.093 |
Renal disease | 0.376 | 0.892 | 0.327–2.430 | 0.263 | 0.393 | 0.076–2.019 |
Obesity | 0.017 | 1.563 | 0.980–2.495 | 0.044 | 1.841 | 1.014–3.341 |
Hypercholesterolemia | 0.213 | 0.929 | 0.450–1.917 | 0.334 | 0.527 | 0.143–1.934 |
Hypertension | 0.586 | 1.645 | 0.971–2.786 | 0.212 | 0.551 | 0.216–1.406 |
Thyroiditis | 0.311 | 1.463 | 0.705–3.033 | 0.417 | 1.517 | 0.554–4.153 |
Chronic pulmonary disease | 0.078 | 0.638 | 0.278–1.463 | 0.046 | 0.228 | 0.053–0.977 |
Other comorbidities | 0.692 | 1.066 | 0.681–1.668 | 0.252 | 1.388 | 0.791–2.435 |